A Trial of High and Low Pressure Level Settings on a Programmable Ventriculoperitoneal Shunt Valve for Idiopathic Normal Pressure Hydrocephalus

NCT01570257 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2016-08-04

No results posted yet for this study

Summary

In treating idiopathic normal pressure hydrocephalus with a shunt there is always a risk of underdrainage or overdrainage. The hypothesis is tested whether treatment of patients with an adjustable valve preset at the highest opening pressure (OPV), leads to comparable clinical results with less subdural effusions than in a control group with an opening pressure preset and kept fixed at a low pressure level.

Conditions

  • Idiopathic Normal Pressure Hydrocephalus

Interventions

PROCEDURE

lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus

in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.

Sponsors & Collaborators

  • Isala

    collaborator OTHER
  • Albert Schweitzer Hospital

    collaborator OTHER
  • UMC Utrecht

    collaborator OTHER
  • Atrium Medical Center

    collaborator OTHER
  • University Medical Center Nijmegen

    collaborator OTHER
  • Admiraal de Ruyter Hospital

    collaborator OTHER
  • Medtronic

    collaborator INDUSTRY
  • Erasmus Medical Center

    lead OTHER

Principal Investigators

  • Clemens MF Dirven, Prof. PhD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2006-12-31
Completion
2007-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01570257 on ClinicalTrials.gov